Third-Line Cohort Added to Phase 2 Pancreatic Cancer Trial for Combination Immunotherapy That Includes Aldoxorubicin, ImmunityBio’s N-803 and NantKwest’s PD-L1 t-haNK
Three Trial Sites in California and South Dakota Will Initially Enroll 298 Patients Across the Cohorts, With 40 Patients Already Enrolled or Being Evaluated
CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today highlighted that ImmunityBio, Inc. and NantKwest, Inc. (collectively, the “Companies”) have announced the addition of a third cohort to their ongoing Phase 2 study of a novel combination immunotherapy – which includes CytRx’s licensed drug aldoxorubicin – for locally advanced or metastatic pancreatic cancer (QUILT-88). According to the Companies, the third cohort will enable pancreatic cancer patients who have failed all approved standards of care to participate in the study.
As previously noted in CytRx’s October 7, 2020 press release regarding